Tompkins Pharmaceutical Rubber Acquires Operating Assets of Amerimold Tech Inc.

Tompkins Pharmaceutical Rubber Corporation, a NJ manufacturer of custom molded rubber products for the pharmaceutical and medical industries, has purchased the operating assets of Amerimold Tech, Inc. of Marlboro, NJ.  A fixture in the custom molding business for more than 60 years, the Amerimold acquisition has expanded Tompkins molding capabilities, particularly in the areas of Liquid Injection Silicone Molding.

Tompkins and Amerimold Tech collectively have more than 165 years experience in the pharmaceutical and medical products industries.  Our expertise and tools are geared for the precise manufacturing and rigors of drug and medical product packaging.

Tompkins is a certified ISO 9000:20001 component manufacturer, with separate molding operations and the use of DI water for cleaning pharmaceutical and medical device products.  The firm maintains a full-time engineering staff, on site quality control laboratory and in house tool and die shop.

In addition to Amerimold Tech’s specialty equipment, Amerimold’s staff, including President Michael Schon are now Tompkins employees.  Amerimold’s key personnel are experienced injection molding professionals.  They have molded miniscule <1mm components and .007-.010 wall thicknesses.  They are an important addition to our already well-versed staff, noting that existing Amerimold customers will be serviced by Tompkins.  

Tompkins Pharmaceutical Rubber offers a variety of molding processes and materials including LIM, compression, transfer and injection molding. 

 

Tompkins Pharmaceutical Rubber Enhances GMP Commitment

Pharmaceutical packaging and medical device component manufacturer Tompkins Pharmaceutical Rubber Corporation announced phase one of major renovation plans to upgrade facilities to cGMP standards.

 

Tompkins initial plans call for adding clean room capabilities, additional Liquid Injection Molding (LIM) presses, and investments in equipment and other plant upgrades. Phase one renovations entail major changes to the layout and expansion of the South Plainfield, NJ factory.

 

The upgrades and renovations will enhance our capabilities and help to facilitate additional pharmaceutical and medical business. Upgrading the facility is a top priority of Tompkins Pharmaceutical.

 

Tompkins will continue to operate under ISO-Certification while undergoing the upgrades. Tompkins’ manufacturing plant is located in South Plainfield, New Jersey. In the current facility, Tompkins utilizes custom-made tools and highly sophisticated equipment designed specifically to manufacture rubber components for the pharmaceutical and medical device industries.

 

Our growing company is committed to innovation and efficiency, to provide the highest quality products and services for our customers.

 

Tompkins Pharmaceutical Rubber Appoints New Technical Director

Tompkins Pharmaceutical Rubber Corporation, a leading provider of custom molded rubber products for the pharmaceutical, medical devices and biotech industries, is pleased to announce the appointment of John Hogan as Technical Director. Hogan is based at the company's South Plainfield, New Jersey headquarters.

 

Hogan, who has spent his entire career in the manufacturing and R & D of polymer based compounds, heads the firm's product development and custom design divisions. He is also overseeing the firm's major renovation plans to upgrade facilities to GMP standards.

 

Since joining Tompkins, Hogan, has also been helping clients take advantage of Tompkin's extensive portfolio of DMFs. "The firm has been in the pharmaceutical business for more than 100 years," he said. Over that time, they have developed many products that have become standards for injectables and medical devices."

 

Hogan, who holds a chemistry degree from St. Francis College in Brooklyn, has also worked closely with clients to develop new applications. "We're very excited about a new type of closure we are developing with a new compound," says Hogan. "Right now, we are in the midst of USP 381 closure testing as a precursor to submission for a new DMF."

 

John has really accelerated our ability to help Tompkins' clients take full advantage of our capabilities. Being based in New Jersey, it's easy to meet with clients and knock out creative solutions to their projects.